No Data
No Data
CereVasc Announces Appointments of New Directors
CereVasc, Inc., a clinical-stage, medical device company developing novel treatments for neurological diseases, today announced the following...
Breaking Down NovoCure: 4 Analysts Share Their Views
4 analysts have expressed a variety of opinions on NovoCure (NASDAQ:NVCR) over the past quarter, offering a diverse set of opinions from bullish to bearish.The table below provides a concise overview
Novocure Is Maintained at In-Line by Evercore ISI Group
Novocure Is Maintained at In-Line by Evercore ISI Group
Evercore Maintains Novocure(NVCR.US) With Hold Rating, Raises Target Price to $20
Evercore analyst Vijay Kumar maintains $Novocure(NVCR.US)$ with a hold rating, and adjusts the target price from $14.5 to $20.According to TipRanks data, the analyst has a success rate of 47.4% and a
Novocure to Report Second Quarter 2024 Financial Results
ROOT, Switzerland–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today that it will report financial results for the second quarter 2024 on Thursday, July 25, 2024, before the U.S. financial marke
Stocks With the Highest and Lowest Liquidity - Goldman Sachs
灵巧的托拜厄斯 : having![undefined undefined](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36)
Kenneil NugentOP : lol no help